Loading
This Brazilian trial tested ivermectin against COVID-19 in people with cancer, not against the cancer itself. It was stopped early because an interim analysis found no difference between the drug and placebo.
The trial opened on 23 July 2020, planned 176 patients and was terminated after enrolling 77 (ClinicalTrials.gov NCT04447235). The registry gives the reason for stopping as 'futility analysis has demonstrated no difference between arms' (ClinicalTrials.gov NCT04447235). No results are posted and no publication was found on Europe PMC (ClinicalTrials.gov NCT04447235). It appears on this page because it is one of only four ivermectin studies on ClinicalTrials.gov that name cancer, and it says nothing about ivermectin as a cancer treatment (ClinicalTrials.gov NCT04447235).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/